Fluarix Tetra suspensija injekcijām pilnšļircē Łotwa - łotewski - Zāļu valsts aģentūra

fluarix tetra suspensija injekcijām pilnšļircē

glaxosmithkline biologicals s.a., belgium - gripas vakcīna (šķelts virions, inaktivēts) - suspensija injekcijām pilnšļircē - 0,5 ml

Influvac suspensija injekcijām Łotwa - łotewski - Zāļu valsts aģentūra

influvac suspensija injekcijām

mylan ire healthcare ltd, ireland - gripas vakcīna (virsmas antigēns, inaktivēta) - suspensija injekcijām pilnšļircē

Infanrix polio suspensija injekcijām pilnšļircē Łotwa - łotewski - Zāļu valsts aģentūra

infanrix polio suspensija injekcijām pilnšļircē

glaxosmithkline biologicals s.a., belgium - difterijas, stingumkrampju, acelulāra garā klepus un poliomielīta (inaktivēta) vakcīna (adsorbēta) - suspensija injekcijām pilnšļircē

VaxigripTetra suspensija injekcijām pilnšļircē Łotwa - łotewski - Zāļu valsts aģentūra

vaxigriptetra suspensija injekcijām pilnšļircē

sanofi pasteur, france - gripas vakcīna (šķelts virions, inaktivēts) - suspensija injekcijām pilnšļircē - 0,5 ml

Kymriah Unia Europejska - łotewski - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - other antineoplastic agents - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Influvac Tetra suspensija injekcijām pilnšļircē Łotwa - łotewski - Zāļu valsts aģentūra

influvac tetra suspensija injekcijām pilnšļircē

viatris healthcare limited, ireland - gripas vakcīna (virsmas antigēns, inaktivēta) - suspensija injekcijām pilnšļircē

Efluelda suspensija injekcijām pilnšļircē Łotwa - łotewski - Zāļu valsts aģentūra

efluelda suspensija injekcijām pilnšļircē

sanofi pasteur, france - gripas vakcīna (šķelts virions, inaktivēts) - suspensija injekcijām pilnšļircē - 0,7 ml

Supemtek Unia Europejska - łotewski - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - gripas, cilvēka - vakcīnas - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Livtencity Unia Europejska - łotewski - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - citomegalovīrusu infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). jāņem vērā oficiālās vadlīnijas par piemērotu izmantot pretvīrusu aģentu.

Clopidogrel Acino Unia Europejska - łotewski - EMA (European Medicines Agency)

clopidogrel acino

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.